James (Jim) French, Contract Specialist

James French serves as a key procurement lead within the National Cancer Institute, supporting the agency’s mission to accelerate translational cancer research through strategic acquisition of scientific and technical services. He manages a diverse portfolio of contracts focused on advanced research infrastructure, diagnostic innovation, and precision medicine technologies, ensuring alignment with NCI’s priorities in genomic analysis and molecular therapeutics. His acquisitions primarily support high-capability laboratories and research consortia, facilitating the deployment of cutting-edge tools essential to cancer discovery and clinical translation. French maintains a strong working relationship with Roche Diagnostics Corporation, a primary vendor for advanced diagnostic platforms and laboratory automation systems. His procurement approach emphasizes partnerships with industry leaders capable of delivering scalable, FDA-aligned technologies, while also fostering collaboration with specialized scientific service providers. He consistently engages vendors with proven expertise in molecular diagnostics, bioinformatics, and clinical trial support systems, ensuring technical rigor and regulatory compliance across awarded contracts. His contracting patterns reflect a balanced commitment to socioeconomic goals, with equal weighting between 8(a) competed set-asides and open, non-set-aside procurements. This approach enables robust competition while actively promoting participation from small disadvantaged businesses with specialized scientific capabilities. French’s strategy supports NCI’s broader equity objectives by creating pathways for 8(a) firms to contribute to high-impact cancer research initiatives. The majority of his acquisitions fall under NAICS 541990 (All Other Professional, Scientific, and Technical Services), reflecting a focus on research support, analytical services, and technical consulting. A smaller but significant portion aligns with NAICS 813920 (Professional Organizations), indicating engagement with scientific societies and research coalitions. His expertise lies in procuring complex, non-commodity services that require deep domain knowledge in oncology, genomics, and translational science.